Tasquinimod

Sök

Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis

Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Büsche G, Kreipe H, Gütgemann I, Krebs P, Banz Y, Boor P, Tai EW, Brümmendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK

Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8. doi: 10.1016/j.stem.2020.11.004

Inhibiting the alarmin-driven hematopoiesis-stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis

Gleitz HFE, Fuchs SNR, Snoeren IAM, Boys C, Nagai J, Tejeda-Mora H, Klöker V, Pritchard JE, Bakker IJ, Gargallo Garasa M, Bindels E, Saez-Rodriguez J, Vogl T, Kramann R, Dugourd A, Costa IG, Schneider RK

Hemasphere. 2025 Aug 14;9(8):e70179. doi: 10.1002/hem3.70179

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Törngren M, Bhalla KN

Blood Adv. 2025 Nov 11;9(21):5598-5609. doi: 10.1182/bloodadvances.2025016898.

S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes

Lin C, Garcia-Gerique L, Bonner EE, Mastio J, Rosenwasser M, Cruz Z, Lawler M, Bernabei L, Muthumani K, Liu Q, Poncz M, Vogl T, Törngren M, Eriksson H, Vogl DT, Gabrilovich DI, Nefedova Y.

Cancer Res Commun. 2023 Mar 13;3(3):420-430

Mechanisms of action of tasquinimod on the tumour microenvironment

Raymond E, Dalgleish A, Damber JE, Smith M, Pili R

Cancer Chemother Pharmacol. 2014 Jan;73(1):1-8. doi: 10.1007/s00280-013-2321-8. Epub 2013

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss

Wobus M, Weidner H, Wehner R, Baumann AL, Möbus K, Balaian E, Törngren M, Vahtola E, Eriksson H, Winter S, Platzbecker U, Chavakis T, Hofbauer LC, Rauner M, Bornhäuser M, Sockel K

Hemasphere. 2026 Apr 14;10(4):e70352. doi: 10.1002/hem3.70352

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma

Satilmis H, Denis A, Verheye E, Van der Vreken A, Zhan D, Calliauw E, Törngren M, Eriksson H, Faict S, De Bruyne E, Menu E, Vanderkerken K, De Veirman K.

J Exp Clin Cancer Res. 2026 May 4. doi: 10.1186/s13046-026-03716-4

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma

H. Satilmis, A. Denis, E. Verheye, E. De Bruyne, E. Menu, M. Törngren, H. Eriksson, K. Venderkerken and K. De Veirman

The poster was presented at American Society of Hematology Annual Meeting (ASH 2025) in Olando, FL, December 6-9, 2025

Clinical Activity of Novel Targeting of S100A9 with Tasquinimod for Relapsed and Refractory Multiple Myeloma (RRMM)

Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Sara Whittington , Cynthia Diaczynsky, Chau T. Nguyen, Inna Strakovsky, Eva Bondesson, Helén Tuvesson, Erik Vahtola, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Adam J. Waxman, Shivani Kapur, Alfred L. Garfall, Edward A. Stadtmauer

The poster was presented at American Society of Clinical Oncology Annual Meeting 2025 (ASCO 2025) in Chicago, IL, May 30 – June 3, 2025

Evaluation of the lethal activity and its mechanism of tasquinimod in advanced myeloproliferative neoplasm (MPN) in blastic phase

Warren Fiskus, Lucia Masarova, Christopher P. Mill, Christine E. Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Kevin Philip, Alicia Matthews, Taghi Manshouri, Surbhi Sharma, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, and Kapil N. Bhalla

Postern presenterades vid det 66:e American Society of Hematology Annual Meeting (ASH 2024) i San Diego, CA, 7-10 december 2024